Risperdal Consta™: The first long-acting atypical antipsychotic agent

P and T

Volumn 29, Issue 9, 2004, Pages 555-562

  Thompson, Suzanne ^a   Rey, Jose A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 2D6; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; MICROSPHERE; PAROXETINE; PHENYTOIN; PLACEBO; POLYGLACTIN; RIFAMPICIN; RISPERIDONE;

AGITATION; AKATHISIA; ANXIETY DISORDER; BIODEGRADABILITY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG METABOLISM; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERKINESIA; INSOMNIA; MUSCLE HYPERTONIA; PATIENT ATTITUDE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RATING SCALE; REVIEW; RHINITIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; TACHYCARDIA; TREATMENT INDICATION; TREMOR; WEIGHT GAIN;

EID: 4544293354     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Crimson ML, Dorson PG. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: A Pathophysiological Approach, 5th ed. New York: McGraw-Hill; 2002:1219-1242.
2. Larco JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002; 63:892-909.
3. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.
4. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21(3): 419-429.
5. Davis JM, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: Place in therapy. Drugs 1994;47:741-773.
6. Risperdal Consta™ (risperidone), package insert. Janssen Pharmaceutica Products LP, October 2003.
7. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(S16):18-23.
8. Love RC. Strategies for increasing treatment compliance: The role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59(S8):S10-S15.
9. Harrison TS, Goa KL. Long-acting risperidone: A review of its use in schizophrenia. CNS Drugs 2004;18(2):113-132.
10. Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003;64(S16):41-46.
11. Cada DJ, Levien T, Baker DE. Risperidone long-acting injection. Hosp Pharm 2004;39(4):353-365.
12. Kane JM, Eerdekens M, Lindenmayer J, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132.
13. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64(10): 1250-1257.